B. Przyklenk

508 total citations
18 papers, 396 citations indexed

About

B. Przyklenk is a scholar working on Pulmonary and Respiratory Medicine, Infectious Diseases and Molecular Biology. According to data from OpenAlex, B. Przyklenk has authored 18 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 6 papers in Infectious Diseases and 5 papers in Molecular Biology. Recurrent topics in B. Przyklenk's work include Cystic Fibrosis Research Advances (10 papers), Antifungal resistance and susceptibility (5 papers) and Bacterial biofilms and quorum sensing (5 papers). B. Przyklenk is often cited by papers focused on Cystic Fibrosis Research Advances (10 papers), Antifungal resistance and susceptibility (5 papers) and Bacterial biofilms and quorum sensing (5 papers). B. Przyklenk collaborates with scholars based in Germany, Switzerland and United States. B. Przyklenk's co-authors include A. Bauernfeind, Gerd Hörl, Gratiana Steinkamp, H. von der Hardt, Félix Ratjen, Gerd Döring, Karsten Harms, R. Jungwirth, C. Petermüller and Richard V. Goering and has published in prestigious journals such as Scandinavian Journal of Gastroenterology, Shock and Pediatric Pulmonology.

In The Last Decade

B. Przyklenk

16 papers receiving 369 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Przyklenk Germany	8	280	112	112	80	60	18	396
R.W. Brimicombe Netherlands	11	248 0.9×	78 0.7×	113 1.0×	41 0.5×	101 1.7×	13	393
A Equi United Kingdom	6	421 1.5×	92 0.8×	176 1.6×	41 0.5×	56 0.9×	7	541
Tim Lee United Kingdom	6	595 2.1×	149 1.3×	140 1.3×	48 0.6×	73 1.2×	7	683
John McCaughan United Kingdom	8	230 0.8×	79 0.7×	49 0.4×	39 0.5×	44 0.7×	24	311
Jill M. Van Dalfsen United States	7	691 2.5×	160 1.4×	129 1.2×	92 1.1×	85 1.4×	8	819
Joseph Hatch United States	8	314 1.1×	181 1.6×	91 0.8×	56 0.7×	33 0.6×	18	451
J.L. Whitehouse United Kingdom	13	298 1.1×	193 1.7×	50 0.4×	62 0.8×	100 1.7×	39	498
Valerie J. Waters Canada	11	368 1.3×	173 1.5×	88 0.8×	39 0.5×	126 2.1×	15	487
Anne Marie Buccat United States	5	161 0.6×	128 1.1×	75 0.7×	86 1.1×	59 1.0×	7	290
Audrey Perry United Kingdom	11	195 0.7×	95 0.8×	167 1.5×	70 0.9×	36 0.6×	27	444

Countries citing papers authored by B. Przyklenk

Since Specialization

Citations

This map shows the geographic impact of B. Przyklenk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Przyklenk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Przyklenk more than expected).

Fields of papers citing papers by B. Przyklenk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Przyklenk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Przyklenk. The network helps show where B. Przyklenk may publish in the future.

Co-authorship network of co-authors of B. Przyklenk

This figure shows the co-authorship network connecting the top 25 collaborators of B. Przyklenk. A scholar is included among the top collaborators of B. Przyklenk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Przyklenk. B. Przyklenk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Steinkamp, Gratiana, Félix Ratjen, A. Bauernfeind, et al.. (1998). Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment ofPseudomonas aeruginosa colonization in cystic fibrosis. Pediatric Pulmonology. 25(2). 88–92. 152 indexed citations

Steinkamp, Gratiana, Félix Ratjen, A. Bauernfeind, et al.. (1998). Placebo‐controlled, double‐blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatric Pulmonology. 25(2). 88–92. 9 indexed citations

Bauernfeind, A. & B. Przyklenk. (1997). Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis.. PubMed. 256–61. 4 indexed citations

Przyklenk, B.. (1997). PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS. Shock. 7(Supplement). 141–142. 1 indexed citations

Przyklenk, B., et al.. (1990). The role of Campylobacter (Helicobacter) pylori in disorders of the gastrointestinal tract. Infection. 18(1). 3–7. 5 indexed citations

Bauernfeind, A., et al.. (1990). Selection of antibiotics for treatment and prophylaxis of staphylococcal infections in cystic fibrosis patients. Infection. 18(2). 126–130. 6 indexed citations

Goering, Richard V., A. Bauernfeind, B. Przyklenk, & W. Lenz. (1990). Staphylococcus aureus in patients with cystic fibrosis: An epidemiological analysis using a combination of traditional and molecular methods. Infection. 18(1). 57–60. 23 indexed citations

Przyklenk, B., et al.. (1990). Evaluation of an IgG-ELISA-kit for diagnosing Helicobacter pylori associated gastroduodenal disease. Serodiagnosis and Immunotherapy in Infectious Disease. 4(4). 263–269. 4 indexed citations

Przyklenk, B., et al.. (1989). Seroimmunological monitoring of Campylobacter pylori in patients with cystic fibrosis. Serodiagnosis and Immunotherapy in Infectious Disease. 3(5). 307–316. 7 indexed citations

10.

Przyklenk, B. & A. Bauernfeind. (1988). Significance of Immunologic Factors in Cystic Fibrosis. Scandinavian Journal of Gastroenterology. 23(sup143). 103–109. 5 indexed citations

11.

Bauernfeind, A., Gerd Hörl, & B. Przyklenk. (1988). Microbiologic and Therapeutic Aspects ofStaphylococcus aureusin Cystic Fibrosis Patients. Scandinavian Journal of Gastroenterology. 23(sup143). 99–102. 10 indexed citations

12.

Przyklenk, B., et al.. (1988). Viral infections of the respiratory tract in patients with cystic fibrosis. Serodiagnosis and Immunotherapy in Infectious Disease. 2(3). 217–225. 5 indexed citations

13.

Bauernfeind, A., Gerd Hörl, R. Jungwirth, et al.. (1987). Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection. 15(4). 270–277. 118 indexed citations

14.

Przyklenk, B., et al.. (1987). Serologic response to candida albicans and aspergillus fumigatus in cystic fibrosis. Infection. 15(4). 308–310. 27 indexed citations

15.

Bauernfeind, A., et al.. (1987). Bacteriological effects of anti-pseudomonas aeruginosa chemotherapy in cystic fibrosis. Infection. 15(5). 403–406. 9 indexed citations

16.

Bauernfeind, A., Gerd Hörl, & B. Przyklenk. (1987). Microbiological perspectives of Co-trimoxazole. Infection. 15(S5). S232–S235. 3 indexed citations

17.

Bauernfeind, A., et al.. (1987). Selective pressure of antistaphylococcal chemotherapeutics in favour of pseudomonas aeruginosa in cystic fibrosis. Infection. 15(6). 469–470. 7 indexed citations

18.

Bauernfeind, A., B. Przyklenk, & C. Petermüller. (1985). [Antibacterial antibodies in immunoglobulins].. PubMed. 35(4). 780–780. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact